Call for Abstracts - 3rd International Conference on HIV Treatment Adherence

March 17-18, 2008
Hyatt Regency Hotel, Jersey City, NJ
Adherence to medical treatment for HIV/AIDS is an essential determinant of treatment success or failure. Yet, we still have much to learn about measurement, determinants, and interventions for HIV treatment adherence — these are complex challenges that require multidisciplinary cooperation among providers, researchers, government agencies, and patients.

The goal of this conference is to provide an international forum for the presentation and discussion of state-of-the-science HIV treatment adherence research, as well as current behavioral and clinical perspectives in practicum. Our ultimate hope is that this dialogue translates into evidence-based implementation of approaches for real world clinical and community settings.

Objectives
After attending this conference, participants will be able to:

  • Identify successes and challenges in HIV treatment adherence in various settings and populations worldwide
  • Understand behavioral and clinical aspects of adherence that reflect a variety of HIV treatment team perspectives (e.g., patients, physicians, pharmacists, nurses, mental health professionals, adherence specialists)
  • Describe the relationships between adherence, pharmacokinetics, viral suppression, and resistance
  • Understand the implications of adherence for HIV prevention and public health
  • Identify adherence assessment tools and interventions that can be integrated into patient care, including in resource-limited settings

Abstract Submissions
All abstracts will be submitted online, a direct link can be found at www.iapac.org. All submitted abstracts will be considered for oral and poster presentations. Late-breaker abstracts will be considered for poster presentations only. All submitted abstracts should report information not previously published, or intended to be published, prior to March 17, 2008.

Oral abstract and poster presenters at the conference must pay their own travel and accommodation expenses, as well as the applicable registration fees. A discounted registration rate is available until November 30, 2007.

It is the responsibility of the presenting author to ensure accuracy of content, spelling, and presentation. Abstracts will be published as submitted, subject to reformatting that may be required by the Conference Organizers.

For further information, please visit:
http://www.iapac.org

About IAPAC
IAPAC (International Association of Physicians in AIDS Care) is recognized under the law of the United States of America as a 501(c)(3) not-for-profit organization. Working in partnership with the healthcare professions, business government, academe, and religious communities, IAPAC accomplishes its mission through a comprehensive program of education, policy and advocacy, direct technical assistance, and care provision initiatives spearheaded by physician members.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...